Vericel Corp
VCEL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000887359
In the last 90 days, Vericel Corp insiders filed 0 open-market purchases and 3 sales; 320 institutions reported holding it in 13F filings for Q2 2026, worth $2.47B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Vericel Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $1.00M in total
- Insiders trading
- 3
- Net value
- −$1.00M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Vericel Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| McLaughlin Kevin F | Director | 18,300 | Aug 14, 2026 | 5 |
| Halpin Michael | Chief Operating Officer | 16,394 | Aug 5, 2026 | 8 |
| Siegal Jonathan | Principal Accounting Officer | 1,078 | Jul 31, 2026 | 6 |
| Hopper Jonathan Mark | Chief Medical Officer | 75,753 | Jun 30, 2026 | 6 |
| Flynn Sean C. | Chief Legal Officer | 1,647 | Jun 30, 2026 | 5 |
| Mara Joseph Anthony Jr | Chief Financial Officer | 16,009 | Jun 30, 2026 | 4 |
| Wotton Paul K | Director | 18,802 | May 13, 2026 | 3 |
| Zerbe Robert L MD | Director | 32,995 | May 1, 2026 | 1 |
| Rubino Alan L | Director | 64,194 | May 1, 2026 | 2 |
| Hagen Heidi | Director | 35,050 | May 1, 2026 | 2 |
| Wright Lisa | Director | 15,851 | May 1, 2026 | 1 |
| Colangelo Dominick | President and CEO | 312,446 | Feb 26, 2026 | 2 |
| Mahoney Karen | Chief Human Resources Officer | 1,854 | Dec 12, 2025 | 1 |
| Gilman Steven C | Director | 11,000 | Oct 18, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2021 (view filing) | Sep 30 | 1 day | Gilman Steven CDirector | SSale | −5.00K | $48.85 | −$244.3K | −58.8%3.50K after | |
| Aug 31, 2021 (view filing) | Aug 27 | 4 days | Flynn Sean C.VP, General Counsel | SSale | −7.20K | $55.11 | −$396.8K | −74.9%2.42K after | |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Halpin MichaelChief Operating Officer | SSale | −15.0K | $48.03 | −$720.5K | −72.7%5.62K after | |
| Jul 23, 2021 (view filing) | Jul 21 | 2 days | Flynn Sean C.VP, General Counsel | SSale | −2.80K | $55.01 | −$154.0K | −53.7%2.42K after | |
| Jul 16, 2021 (view filing) | Jul 15 | 1 day | Flynn Sean C.VP, General Counsel | SSale | −10.0K | $51.18 | −$511.8K | −80.5%2.42K after | |
| Jul 14, 2021 (view filing) | Jul 12 | 2 days | Halpin MichaelChief Operating Officer | SSale | −20.0K | $53.54 | −$1.07M | −78.1%5.62K after | |
| Jul 2, 2021 (view filing) | Jun 30 | 2 days | Hopper Jonathan MarkChief Medical Officer | SSale | −134 | $57.14 | −$7.66K | −0.3%39.3K after |